| 查看: 523 | 回复: 1 | ||
| 本帖产生 1 个 翻译EPI ，点击这里进行查看 | ||
[求助]
急求外文一段摘要翻译，谢谢
|
||
| Triptans are a new class of compounds developed for the treatment of migraine attacks. The first of the class, sumatriptan, and the newer triptans (zolmitriptan, naratriptan, rizatriptan, eletriptan, almotriptan and frovatriptan) display high agonist activity at mainly the serotonin 5-HT1B and 5-HT1D receptor subtypes. As expected for a class of compounds developed for affinity at a specific receptor, there are minor pharmacodynamic differences between the triptans. Sumatriptan has a low oral bioavailability (14%) and all the newer triptans have an improved oral bioavailability and for one, risatriptan, the rate of absorption is faster. The half-lives of naratriptan, eletriptan and, in particular, frovatriptan (26 to 30h) are longer than that of sumatriptan (2h). These pharmacokinetic improvements of the newer triptans so far seem to have only resulted in minor differences in their efficacy in migraine. Double-blind, randomised clinical trials (RCTs) comparing the different triptans and triptans with other medication should ideally be the basis for judging their place in migraine therapy. In only 15 of the 83 reported RCTs were 2 triptans compared, and in 11 trials triptans were compared with other drugs. Therefore, in all placebo-controlled randomised clinical trials, the relative efficacy of the triptans was also judged by calculating the therapeutic gain (i.e. percentage response for active minus percentage response for placebo). The mean therapeutic gain with subcutaneous sumatriptan 6mg (51%) was more than that for all other dosage forms of triptans (oral sumatriptan 100mg 32%; oral sumatriptan 50mg 29%: intranasal sumatriptan 20mg 30%; rectal sumatriptan 25mg 31%; oral zolmitriptan 2.5mg 32%; oral rizatriptan 10mg 37%; oral eletriptan 40mg 37%; oral almotriptan 12.5mg 26%). Compared with oral sumatriptan 100mg (32%), the mean therapeutic gain was higher with oral eletriptan 80mg (42%) but lower with oral naratriptan 2.5mg (22%) or oral frovatriptan 2.5mg (16%). The few direct comparative randomised clinical trials with oral triptans reveal the same picture. Recurrence of headache within 24 hours after an initial successful response occurs in 30 to 40% of sumatriptan-treated patients. Apart from naratriptan, which has a tendency towards less recurrence, there appears to be no consistent difference in recurrence rates between the newer triptans and sumatriptan. Rizatriptan with its shorter time to maximum concentration (tmax) tended to produce a quicker onset of headache relief than sumatriptan and zolmitriptan. The place of triptans compared with non-triptan drugs in migraine therapy remains to be established and further RCTs are required. |
回复此楼» 猜你喜欢
287分求调剂 有专利国奖一志愿哈工大085406
已经有4人回复
-
285求调剂
已经有7人回复
-
085405软件工程301分求调剂，专硕可跨专业，四六级已过
已经有3人回复
-
求调剂
已经有5人回复
-
274求调剂求调剂
已经有3人回复
-
求调剂到材料
已经有5人回复
-
材料考研求调剂总分280
已经有5人回复
-
一志愿郑州大学材料与化工085600，求调剂
已经有27人回复
-
化工求调剂！
已经有11人回复
-
285求调剂
已经有4人回复
xiao_hu
木虫 (著名写手)
Tiny
- 翻译EPI: 29
- 应助: 22 (小学生)
- 金币: 1800.7
- 散金: 200
- 红花: 1
- 帖子: 2197
- 在线: 89.1小时
- 虫号: 1989552
- 注册: 2012-09-10
- 性别: GG
- 专业: 药物化学
【答案】应助回帖
★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★
霜叶: 金币+10, 翻译EPI+1, 翻译辛苦了，谢谢 2013-03-20 16:48:17
phu_grassman: 金币+10, 金币代发。 2013-03-24 09:54:21
霜叶: 金币+10, 翻译EPI+1, 翻译辛苦了，谢谢 2013-03-20 16:48:17
phu_grassman: 金币+10, 金币代发。 2013-03-24 09:54:21
| 曲坦类药物是一类新的化合物开发治疗偏头痛发作。第一个类,作为舒马曲坦和新的曲坦类药物(佐米曲坦）显示高5 -羟色胺受体激动剂主要活动5-HT1B和5-HT1D受体亚型。如预期的一类化合物开发在一个特定的受体的亲和力,会有小的药效学差异曲坦类药物。口服生物利用度作为舒马曲坦低(14%)和所有的新曲坦类药物口服生物利用度和改进,吸收的速度更快。。这些药代动力学改进新的曲坦类药物目前为止似乎只有微小差别导致其功效在偏头痛。双盲、随机临床试验比较不同与其他药物曲坦类药物和曲坦类药物应该是依据他们的位置来判断在偏头痛治疗。在83年的报道只有15冥想是2曲坦类药物比较,在11个试验与其他药物比较曲坦类药物。因此,在所有随机安慰剂对照临床试验,相对有效性的鉴定由计算曲坦类药物治疗增益(即百分比响应百分比响应积极减去安慰剂)。平均治疗增益与皮下作为舒马曲坦6毫克(51%)超过所有其他剂型的曲坦类药物(口服100毫克作为舒马曲坦32%;口腔作为舒马曲坦50毫克29%:鼻作为舒马曲坦20 mg的30%;直肠作为舒马曲坦25 mg 31%;口服佐米曲坦2.5毫克口服 32%;10毫克37%;口腔 40毫克37%;口腔12.5毫克的26%)。作为舒马曲坦相比口服100毫克(32%),平均治疗增益较高口服80毫克(42%),但较低的口服 2.5毫克(22%)或口头 2.5毫克(16%)。为数不多的直接比较的随机临床试验显示同样的画面口服曲坦类药物。头痛复发后24小时之内最初成功的响应发生在30 ~ 40%的病人治疗作为舒马曲坦。除了减少复发倾向,似乎没有一致的差异之间的复发率较新的曲坦类药物和作为舒马曲坦。以其短时间最大浓度(达峰时间)倾向于产生更快缓解头痛发作的比作为舒马曲坦和佐米曲坦。曲坦类药物的地方而非曲普坦药物治疗偏头痛仍有待建立和进一步需要冥想。 |
2楼2013-03-20 12:54:07
